Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Zogenix (ZGNX) Message Board

Latest Zogenix Inc (ZGNX) Headlines Super Paink

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 28
Posted On: 03/13/2014 4:34:18 AM
Avatar
Posted By: Stock_Tracker
Latest Zogenix Inc (ZGNX) Headlines

Super Painkiller May Be in Trouble
David Williamson, The Motley Fool - Motley Fool - Wed Mar 12, 5:47PM CDT
Shares of Zogenix took an awful 20% haircut today, on news emerging from a potential competitor. Zogenix's new super painkiller, Zohydro, is extremely potent and effective, normally a positive thing for a drug, but an advisory panel overwhelmingly...

Why Zogenix (ZGNX) Is Down Big Today
at The Street - Wed Mar 12, 3:38PM CDT
Zogenix ZGNX shares are down as much as 22.7% this afternoon on the news that rival Purdue Pharma has completed testing of an abuse-resistant version of its painkiller hydrocodone. Purdue Pharma, which also produces the popular painkiller OxyContin,...

PulteGroup and Herbalife are big market movers
AP - Wed Mar 12, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily XXX on the New York Stock Exchange and the Nasdaq Stock Market:

OxyContin maker to offer abuse-resistant Zohydro
By MATTHEW PERRONE - AP - Wed Mar 12, 3:13PM CDT
WASHINGTON (AP) — The maker of OxyContin says it has completed testing of an abuse-resistant version of the painkiller hydrocodone, a surprise development that could derail sales of the recently launched Zohydro, a similar medication that has been criticized for lacking such safeguards.

Geron, Zogenix, Synta Pharmaceuticals, and Pfizer: Today’s Top Health Care Stories
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 12, 8:39AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at four companies -- Geron , ...

Zogenix (ZGNX) Jumps: Stock Moves 11.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:25AM CDT
Zogenix was a big mover last session, with shares rising nearly 12%.

Why Knightsbridge Tankers, PowerSecure International, and Zogenix Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Mar 11, 7:00PM CDT
On Tuesday, there was an apparent change in psychology among investors that went beyond the modest declines in the major market averages. Even though most benchmarks fell only by half a percent or so, many formerly high-flying momentum stocks came...

GM and Electronic Arts are big market movers
AP - Tue Mar 11, 4:20PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:

Dr. Marsha Stanton Receives 2014 American Academy of Pain Medicine Distinguished Service Award
GlobeNewswire - Fri Mar 07, 9:23AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the American Academy of Pain Medicine (AAPM) has presented Marsha R. Stanton, Ph.D., RN, Executive Director of Medical Affairs at Zogenix, with the Distinguished Service Award, recognition given annually to honor an individual for their outstanding commitment and contributions to the field of pain medicine and the AAPM.

Trade-Ideas: Zogenix (ZGNX) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Mar 07, 8:45AM CST
Trade-Ideas LLC identified Zogenix (ZGNX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Why Zogenix, Inc. Was a House of Pain for Investors
David Williamson, The Motley Fool - Motley Fool - Thu Mar 06, 6:44PM CST
Zogenix just took a painful one-two punch on the market today, causing shares to fall 15%. First, the company reported Q4 earnings, which missed estimates; but that wasn't the real story with the company today. Much more painful to the stock was...

Why Zogenix Inc. Shares Swooned
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 06, 1:32PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Zogenix , a biopharmaceutical company...

'Mad Money' Lightning Round: Steer Clear of Tesla
at The Street - Thu Mar 06, 5:00AM CST
Cramer is disappointed by Chegg and prefers Schlumberger over Hercules Offshore.

Jim Cramer's 'Mad Money' Recap: Beware the Bears
at The Street - Wed Mar 05, 7:03PM CST
Don't let them scare you out of this market, Cramer says.

Zogenix Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Mar 05, 3:06PM CST
Business Highlights and Milestones

Ahead of the Bell - Top Gainers LiveDeal, Ur-Energy, Zogenix, Quantum Fuel Systems Technologies Worldwide and JA Solar Holdings
PR Newswire - Wed Mar 05, 10:10AM CST
Editor Note: For more information about this release, please scroll to bottom.

Zogenix Reports Granting of Inducement Awards
GlobeNewswire - Wed Mar 05, 7:30AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to 102 new non-executive employees.

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Feb 27, 3:51PM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it will release financial results for the fourth quarter and full year ended December 31, 2013, after the market closes on Wednesday, March 5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.


(0)
(0)




Zogenix (ZGNX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us